By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
CryptoCommunityCryptoCommunity
  • Home
  • General
  • Blockchain
  • Crypto
  • DeFi
  • Metaverse
  • NFT
Search
  • BTC
  • ETH
  • USDT
  • USDC
  • BNB
  • BUSD
  • ADA
  • XRP
  • SOL
  • DOGE
  • DOT
  • MATIC
Reading: Clerkenwell Health raises £2.1m to test the new wave of psychedelics treatments
Share
Aa
CryptoCommunityCryptoCommunity
Aa
  • Home
  • General
  • Blockchain
  • Crypto
  • DeFi
  • Metaverse
  • NFT
Search
  • Home
  • General
  • Blockchain
  • Crypto
  • DeFi
  • Metaverse
  • NFT
Follow US
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
CryptoCommunity > Blog > General > Clerkenwell Health raises £2.1m to test the new wave of psychedelics treatments
General

Clerkenwell Health raises £2.1m to test the new wave of psychedelics treatments

admin Published October 10, 2022
Last updated: 2022/10/10 at 1:44 PM
Share
SHARE

[ad_1]

Clerkenwell Health, a psychedelic-specialist clinical research organisation, has raised £2.1m in seed funding, bringing the total to date up to £2.5m, which will be used to get the London startup-based fully operational.

Investors include Lionheart Ventures, Convergence Partners, and Exceptional Ventures, which was co-founded by Paolo Pio (former MD Europe at Joyance Partners) and Matt Cooper (who was part of the founding team at Capital One Bank in the US, co-founder of Tandem Bank and Chairman of Octopus Capital Group).

Claiming to be Europe’s first commercial facility dedicated to psychedelic-assisted therapies, Toronto-based life sciences company Psyence will now kick off its first trials at Clerkenwell’s London site, following its approval from the MHRA.

The clinical trial will assess the efficacy and safety of psilocybin-assisted psychotherapy versus psychotherapy alone for the treatment of adjustment disorder due to an incurable cancer diagnosis. Data from the UK’s Office of National Statistics suggests the suicide risk for terminally ill people is twice that of the general population.

As we’ve detailed before, drugs which were previously relegated to underground communities and rave culture – drugs like ketamine, MDMA (commonly known as ecstasy) and psilocybin – are now being studied to develop therapies to treat everything from PTSD to cluster headaches.

Tom McDonald, CEO of Clerkenwell Health, said in a statement: “The UK is extremely well-placed to become the  leader in psychedelics research and trials thanks to its globally competitive framework for clinical trials, which is why we chose to launch our operations in London.”

Most research related to psychedelics is currently happening in universities and hospitals. Other psychedelic drug facilities are being built (Compass Pathways x South London and Maudsley NHS Trust) but they tend to be built by drug developers so are designated to a single company or compound. By contrast, Clerkenwell Health says it will work with multiple drug developers.

Paolo Pio, Co-Founder and General Partner of Exceptional Ventures, added: “Psychedelics show great promise in treating mental disorders, but it is a complex and highly regulated field. Clerkenwell Health founders bring together years of experience in this area, and we believe they are the best positioned in the UK and Europe.”
Clerkenwell Health is also working with North American drug discovery and biotechnology companies, notably the Otsuka Pharmaceutical-backed Mindset, which focuses on treatments for neurological and psychiatric disorders.

[ad_2]

You Might Also Like

Revyze is building the TikTok of educational videos

YouTube ends the test asking users to get a premium subscription to watch 4K videos

Who is going to buy Cadillac’s $300,000 hand-built EV?

Don’t let today’s software rally improve your mood

Daily Crunch: Kanye West reaches agreement to acquire social media platform Parler

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.
[mc4wp_form]
By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
admin October 10, 2022
Share this Article
Facebook TwitterEmail Print
Share
Previous Article TA: Ethereum Price at Make-or-Break Levels, Rally Remains Attractive To Sellers
Next Article Google removes The OG App from the Play Store as founders think about next steps

Latest News

earn bitcoins fast
How to earn bitcoins fast
crypto
Cryptocurrency is a Scam or Not
How to Tell If a Cryptocurrency is a Scam or Not
crypto
Losing In Cryptocurrency Trading
Tips to Avoid Losing In Cryptocurrency Trading
crypto
Sell Products Online with Bitcoins
How to Sell Products Online with Bitcoins – The Ultimate Guide
crypto

You Might also Like

Revyze is building the TikTok of educational videos

6 Min Read

YouTube ends the test asking users to get a premium subscription to watch 4K videos

2 Min Read

Who is going to buy Cadillac’s $300,000 hand-built EV?

4 Min Read

Don’t let today’s software rally improve your mood

1 Min Read

Crypto Community

  • Home
  • Crypto Calculator
  • Blog
  • Contact Us
  • Privacy Policy
  • Disclaimer
  • Terms and Conditions

Real time Cryptocurrency

  • Crypto Prices
  • Dogecoin price
  • Shibainu coin price
  • Bitcoin Price
  • Cardano Price
  • Litecoins Price

Cryptocurrency Price USD

  • Bitcoin price USD
  • Ethereum price USD
  • Tether price USD
  • BNB Price USD
  • Cardano Price USD
  • Solana Price USD
  • Peps coin Price USD
  • floki inu Price USD
  • SIA coin Price USD
CryptoCommunityCryptoCommunity
Follow US

© 2022 Cryptos Community All Rights Reserved. All logos and images used on this website are registered trademarks of their respective companies. All Rights Reserved. Cryptos Community is not liable for inaccuracies, errors, or omissions found herein. For the removal of copyrighted images, trademarks, or other issues, Contact Us. 


Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?